Provectus Biopharma (PVCT) Reports Q2 Loss of $0.02/Share
Tweet
Share
E-mailGet Alerts PVCT Hot Sheet
Price: $0.05 --0%
Financial Fact:
Research and development: 2.46M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Financial Fact:
Research and development: 2.46M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Join SI Premium – FREE
Provectus Biopharma (NYSE: PVCT) reported Q2 EPS of ($0.02), versus ($0.02) reported last year.
Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.
For earnings history and earnings-related data on Provectus Biopharma (PVCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
